BZE2204 represents a novel CAR-T cell therapy targeting multiple antigens (CD19, CD22, and BCMA) for the treatment of relapsed or refractory autoimmune diseases, specifically idiopathic inflammatory myopathies (IIM), immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE). The market for autoimmune therapies is significant, with increasing demand for innovative treatments due to the limitations of current therapies. The competitive landscape includes other CAR-T therapies and biologics targeting similar conditions, but BZE2204's tri-target approach may provide a unique selling proposition. The trial is currently recruiting, with anticipated completion in late 2027, suggesting a potential market entry around 2028, contingent on successful outcomes. Diligence should focus on safety and efficacy data, as well as regulatory pathways in China and potentially other markets.